We have demonstrated that CARs comprising an scFv against broadly representative targets CD19, HER2, and mesothelin, a CD8 hinge and transmembrane domain, and the CD3ζ intracellular domain efficiently redirect macrophages, guiding antigen dependent phagocytosis, cytokine release, and anti-tumor activity (67). Here, ERBB2 is linked to neoplasm.